Betta Pharmaceuticals Co Ltd (300558 SHE) stock market data APIs
¥58.0506
0.53(0.9%)
as of July 4, 2025
Try our APIs with
free plan!
Betta Pharmaceuticals Co Ltd Financial Data Overview
Price chart is built with
Anychart
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is based in Hangzhou, China.
Prev. Close
58.0506
Open
58.5774
High
59.9754
Low
57.4686
52 wk Range
29.7255-64.9605
Market Cap
24 394 M
P/E Ratio
60.3958
Shares Outstanding
421 M
Revenue
3 074 M
EPS
0.24
Dividends (Yield)
0.0034
Beta
0.536
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Betta Pharmaceuticals Co Ltd data using free add-ons & libraries
Get Betta Pharmaceuticals Co Ltd Fundamental Data
Betta Pharmaceuticals Co Ltd Fundamental data includes:
- Net Revenue: 3 074 M
- EBITDA: 950 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-24
- EPS/Forecast: 0.45
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Betta Pharmaceuticals Co Ltd News
New
TT Electronics plc's (LON:TTG) Intrinsic Value Is Potentially 59% Above Its Share Price
How far off is TT Electronics plc (LON:TTG) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows ...
Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China
- Agenus to receive $35M upfront with $100M in milestones plus royalties - Betta receives exclusive license of balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4) in Greater China LEXINGTON, Mass...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
